Two more FXR agonists, LMB763 (NCT02913105) and LJN452 (NCT02855164), are also under clinical investigation to test their effects on safety, tolerability, and liver inflammation in patients with NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.